Presentation of 1-year IVAN and 2-year CATT study results

April 18th, 2012
Rockville, Md.: ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.

These two multicenter randomized clinical trials, sponsored by the National Institute of Health Research in the United Kingdom and the National Eye Institute, respectively, evaluate the relative efficacy and safety of Lucentis and Avastin in the management of neovascular age-related macular degeneration (AMD).

The presentation will also live-streamed at http://prolibraries.com/arvo/registration/event. While annual meeting registration is required for the session in Fort Lauderdale, the online is event is free.

The 2012 ARVO Annual Meeting, Translational Research: Seeing the Possibilities, takes place May 6 – 10 in Fort Lauderdale, Fla. Registration information can be found at www.arvo.org/am.

Provided by Association for Research in Vision and Ophthalmology

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

Giant methane storms on Uranus

Most of the times we have looked at Uranus, it has seemed to be a relatively calm place. Well, yes its atmosphere is the coldest place in the solar system. But, when we picture the seventh planet in our ...

Desmoplakin's tail gets the message

Cells control the adhesion protein desmoplakin by modifying the tail end of the protein, and this process goes awry in some patients with arrhythmogenic cardiomyopathy, according to a study in The Journal of ...

Should Australia consider thorium nuclear power?

Australia has developed something of an allergic reaction to any mention of uranium or nuclear energy. Blessed as we are with abundant reserves of coal, oil and gas, we have never had to ask the hard questions ...